Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Sundia MediTech Rides WuXi IPO to Series B Funding

publication date: Jan 18, 2008

Sundia MediTech Company, a Shanghai-based CRO, has completed its second round of capital funding, though the amount raised was not disclosed. Sundia said that the fund raising has been underway since last summer, about the time that WuXi PharmaTech made its IPO on the NYSE. Company officials said that the success of the WuXi offering helped Sundia in its efforts. It also didn’t hurt that, last summer, Sundia was also ranked as number 16 on the Venture 50 list, a ranking of the most promising investment opportunities in China put together by investment house Zero2IPO. More details...

Stock Symbol: (NYSE: WX) 



Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Upcoming Events

ChinaBio® Partnering Forum
September 10–11, 2024 | Shanghai, China
Register here

BIO-Europe®
November 4–6, 2024 | Stockholm, Sweden
Save €900 before September 13!
Register here

Biotech Showcase™
January 13–15, 2025 | San Francisco, CA
Save $600 before September 27!
Other Relevant Events

Antibody Engineering & Therapeutics Asia
October 21–23, 2024 | Kyoto, Japan
Save 30% with code CHINABIO30!
Register here